Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old

Go back to Resources

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine

Go back to Resources

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Rheumatologist Care in Rheumatoid Arthritis: Are We Dropping the Ball?

Go back to Resources

Rheumatologist Care in Rheumatoid Arthritis: Are We Dropping the Ball?

Authors:

Secondary:

Location:

URL:

Go back to Resources

Recruitment and Retention in a Long-Term Prospective Observational Investigation of Pregnant Women with Epilepsy

Go back to Resources

Recruitment and Retention in a Long-Term Prospective Observational Investigation of Pregnant Women with Epilepsy

Authors:

Secondary:

Location:

URL:

Abstract:

Go back to Resources

Race and Ethnicity Differences in a MI-Based Brief Intervention Delivered in an ED Setting

Go back to Resources

Race and Ethnicity Differences in a MI-Based Brief Intervention Delivered in an ED Setting

Authors:

Secondary:

Location:

URL:

Go back to Resources

Quality Issues in Clinical Research - Auditing for Improved Protocol Compliance

Go back to Resources

Quality Issues in Clinical Research - Auditing for Improved Protocol Compliance

Authors:

Secondary:

Location:

URL:

Go back to Resources

Progression of Vision Loss in Macular Telangiectasia Type 2

Go back to Resources

Progression of Vision Loss in Macular Telangiectasia Type 2

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Predictors of Agreement Between Hair Analysis and Self-Report of Drug Use

Go back to Resources

Predictors of Agreement Between Hair Analysis and Self-Report of Drug Use

Authors:

Secondary:

Location:

URL:

Go back to Resources

The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy

Go back to Resources

The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy

Authors:

Volume:

Pagination:

Issue:

Journal:

PMID:

URL:

Keywords:

Abstract:

Go back to Resources

Regulation of Cellular Therapy in the United States

Go back to Resources

Regulation of Cellular Therapy in the United States

Authors:

Secondary:

Pagination:

Publisher:

Editor(s):

URL:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 225
  • Page 226
  • Page 227
  • Page 228
  • Current page 229
  • Page 230
  • Page 231
  • Page 232
  • Page 233
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification